CancerDrs

Prostate Cancer clinical trials in Indiana

17 actively recruiting prostate cancer trials at 8 sites across Indiana.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Indiana:
  • Goshen Center for Cancer Care — Goshen, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Indiana:
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Indiana:
  • Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Indiana:
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Indiana:
  • Research Site — Fort Wayne, Indiana
  • Research Site — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Indiana:
  • Urology of Indiana - Carmel ( Site 0055) — Carmel, Indiana
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…

Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Indiana:
  • Research Site — Greenwood, Indiana
  • Research Site — Jeffersonville, Indiana
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Indiana:
  • Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

PSMA-PET to Guide Prostatectomy

In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount p…

Sponsor: Five Eleven Pharma, Inc.
NCT ID: NCT05381103
Sites in Indiana:
  • Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Indiana:
  • Urology of Indiana — Carmel, Indiana
  • First Urology — Jeffersonville, Indiana
  • Urologic Specialists of Northwest Indiana — Merrillville, Indiana
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).

Sponsor: Pathos AI, Inc.
NCT ID: NCT06785636
Sites in Indiana:
  • Community Health Network — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prosta…

Sponsor: Clinton Bahler
NCT ID: NCT06849544
Sites in Indiana:
  • Indiana University Health North Hospital — Carmel, Indiana
  • Indiana University Health Methodist Hospital — Indianapolis, Indiana
  • Indiana University School of Medicine — Indianapolis, Indiana
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Indiana:
  • Indiana University — Indianapolis, Indiana
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana:
  • Reid Health — Richmond, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .

Sponsor: Indiana University
NCT ID: NCT05879913
Sites in Indiana:
  • IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
  • Methodist Hospital — Indianapolis, Indiana
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Evaluating Tolerability of ePUHRT With Brachytherapy Boost

The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radioth…

Sponsor: Indiana University
NCT ID: NCT06817668
Sites in Indiana:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25